Ribomic Inc
TSE:4591
Relative Value
The Relative Value of one Ribomic Inc stock under the Base Case scenario is 19.11 JPY. Compared to the current market price of 84 JPY, Ribomic Inc is Overvalued by 77%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Ribomic Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
JP |
Ribomic Inc
TSE:4591
|
3B JPY | 47.8 | -3.1 | 0.5 | 0.5 | ||
US |
Abbvie Inc
NYSE:ABBV
|
286.8B USD | 5.3 | 59.5 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
146.6B USD | 5.2 | 21.8 | 16.3 | 24.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.8B USD | 10.3 | 28.1 | 22.4 | 23.5 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.7B USD | 7.5 | 24.7 | 16.3 | 18 | ||
AU |
CSL Ltd
ASX:CSL
|
133.7B AUD | 6.2 | 35.5 | 21.5 | 26.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.3B USD | 3 | 14.4 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.5B USD | 6.2 | -9 | -9.5 | -8.1 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.4B USD | 3.2 | 27.1 | 14.6 | 18.1 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |